Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus Ipilimumab in Recurrent/Metastatic Salivary Cancers
NCT03172624Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2017
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in salivary gland cancer (SGC) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Overall Response Rate at 2 years. Started May 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT03172624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172624.